Summit announced an expansion of its license territories for ivonescimab via an amendment of the collaboration and in-license agreement with Akeso, Inc. Under the terms of the expanded agreement, Summit?s license territories for ivonescimab will include Latin America, including Mexico and all countries in Central America and South America, in addition to the Middle East and Africa. This expansion adds to the territory licensed by Summit, which previously included the United States, Canada, Japan, and Europe.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
39.1 HKD | +2.22% |
|
+2.23% | -16.06% |
04/06 | Akeso Expands Territory of License Agreement for Lung Cancer Drug | MT |
03/06 | Summit Therapeutics Inc. Expands License Territories for Ivonescimab | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
39.1 HKD | +2.22% | +2.23% | 4.24B | ||
8.01 USD | +0.12% | +0.88% | 5.62B | ||
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.06% | 4.24B | |
+16.45% | 123B | |
+21.96% | 115B | |
+23.73% | 25.85B | |
-20.05% | 20.9B | |
-16.28% | 16.77B | |
-16.52% | 16.52B | |
-44.35% | 15.56B | |
+63.91% | 15.49B | |
+2.52% | 13.45B |
- Stock Market
- Equities
- 9926 Stock
- News Akeso, Inc.
- Summit Therapeutics Inc. Expands License Territories for Ivonescimab